Latest Biochip News

Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012SPECIAL EXCLUSIVE - Save 10% now by using coupon code KFBD12 when registering. Code expires Wednesday May 30th, 2012. Boston, MA (PRWEB) May 24, 2012 BIODETECTION TECHNOLOGIES 2012 - the 20th conference in our Detection Technologies conference series - is an internationally recognized event for experts in detection & identification of biological threats. This conference will review feedback f...

Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter Preclinical Development in Acute Leukemia and Other Hematological CancersOryzon announced today that it is entering preclinical development with its second drug candidate, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of hematological cancers. LSD1 inhibition reduced tumor load especially in acute leukemia models by targeting Leukemia Stem Cells, while normal myeloid progenitor cells were spared. Barcelona, Spain (PRWEB) May...

Firefly BioWorks, Inc. Announces the Award of a $500K Grant from the Massachusetts Life Sciences CenterFirefly BioWorks, Inc., a developer of next-generation multiplexed assays for biomarker detection, announced today the awarding of a $500K Grant from the Massachusetts Life Sciences Center. The award was granted through the Center's Small Business Matching Grant Program, which was created to accelerate the commercialization of new products for companies th...

MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & SullivanLONDON, May 23, 2012 /PRNewswire/ -- A number of large pharmaceutical and biotech companies are keen to invest in life science research. Advances in genomic technologies and molecular biology segments will boost the microRNA (miRNA) research and tools market in the future. MicroRNA is set to unveil a new era in molecular diagnostics and in the development of effective therapeutics. New analy...

New Website Reflects Strategic FocusSurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic (IVD) technologies to the healthcare industry, is pleased to announce the launch of its new website, www.surmodics.com. The website, revealed earlier this year, reflects SurModics' strategic focus on its two core businesses: Me

DDC Announces Harvard University Partnership in Conjunction with National DNA Testing Standard for Tissue Culture AuthenticationDDC (DNA Diagnostics Center), one of the largest DNA testing companies in the world, announces its new partnership with Dr. Pelish and the Chemistry and Chemical Biology Department at Harvard University to authenticate cell lines used in its research projects. DDC is also proud to announce university affiliations with the University of Virginia's Department of Pathology and the University of...

AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstratedBRANFORD, Conn., May 21, 2012 /PRNewswire/ -- HistoRx, the leader in quantitative immunohistochemistry, announces the application of their proprietary AQUA technology to assessment of messenger RNA in tissue. AQUA technology enables robust quantification and standardization of protein in tissue specimens; this new work extends the platform's capabilities beyond protein expression analys...

Deletion of 'lunatic fringe' promotes tumor formation of basal-like breast cancersMultiple research projects - including a 2006 study conducted at the University of North Carolina at Chapel Hill - have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enric...

Aushon to Launch New Multiplex Immunoassay PlatformBILLERICA, Mass., May 21, 2012 /PRNewswire/ -- Aushon announced its plans today for an upcoming global launch of its new multiplex protein biomarker platform, which incorporates several engineering breakthroughs to deliver ELISA-level performance. Aushon's ultra-precise microarray printing, novel assay design, astronomy-grade imaging and advanced analytics provide the sensitivity and re...

Caris Target Now™ Data to be Showcased at ASCO 2012IRVING, Texas, May 21, 2012 /PRNewswire/ -- Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced that eight data presentations on Caris Target Now™, the foremost evidence-based molecular profiling service, will take place next month at the 2012 annual me...

GenVec Appoints Cynthia Collins as President and CEOGAITHERSBURG, Md., May 21, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that effective May 23, 2012 Cynthia Collins has been appointed as President and Chief Executive Officer. In addition, Ms. Collins is expected to be appointed to the Board of Directors of GenVec. Effective upon Ms. Collins' appointment, Paul H. Fischer, Ph.D. will step down as GenVec's President an...

Cancer Genetics continuing with IPO plansContrary to media reports saying otherwise, Cancer Genetics Inc. (Rutherford, N.J.) has not postponed its planned IPO, according to a source familiar with the deal. The source said the market conditions are "not ideal" but added that the company is s...

SQI closes second tranche of private placementSQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced today it has raised gross proceeds of CDN $2.333 million through the second tranche of...

Affymetrix and ScreenCell Announce Worldwide Distribution Agreement for Circulating Tumor Cell (CTC) TechnologyAffymetrix, Inc. (NASDAQ: AFFX) and ScreenCell, a privately-held company, today announced the signing of a worldwide distribution agreement for ScreenCell’s isolation devices and dilution buffers,* designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood. The agreement makes Affymetrix the exclusive distributor of...

Lineagen Completes 9000-Person Study Focused on Genetic Variants in Individuals Diagnosed with Autism Spectrum Disorder (ASD)SALT LAKE CITY, May 17, 2012 /PRNewswire/ -- Lineagen today announced the Company completed the testing portion of a 9,000-person research study designed to confirm novel copy number genetic variants and novel next-generation sequence variants associated with autism spectrum disorder (ASD). These variants were discovered by Hakon Hakonarson, M.D., Ph.D., and his team at The Children's H...

The Biodesign Institute® at Arizona State University taps HighRes Biosolutions for simplifying upstream sample preparation of protein microarraysThe Biodesign Institute at Arizona State University has reached an agreement with HighRes Biosolutions to automate DNA sample preparation of Nucleic Acid Programmable Protein Arrays (NAPPA) using a flexible dual NanoCell™ laboratory automation system. The dual NanoCell system was selected by Dr. Joshua LaBaer, director of the Institute’s Virginia G. Pi...

Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing ApplicationsANN ARBOR, Mich., May 16, 2012 /PRNewswire/ -- Rubicon Genomics, Inc., a leader in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for research and clinical testing, today announced the launch of the first product in its innovative ThruPLEX™ family of sample preparation kits...

Microarray for Detection and Subtyping of Human Influenza VirusesAvailable for licensing and commercial development are a novel influenza virus microarray and methods for using the microarray for the identification of existing and new types and subtypes of human influenza viruses. There are three types of influenza viruses, type A, B and C. Influenza types A or B viruses cause epidemics of disease almost every winter, with type A causes major pandemic periodi...

SurModics IVD to Present at Biomarker World Congress in Philadelphia, PASurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for immunoassay reagents for diagnostic tests, is pleased to announce it will present a poster entitled “Evaluation of Immunoassay Interference Reduction Technologies” at Biomarker World Congress in Philadelphia, PA from May 21 – 23, 2012....

IBNs droplet array sheds light on cancer stem cellsResearchers at the Institute of Bioengineering and Nanotechnology (IBN), the worlds first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs).

Miniaturized biochip can investigate effect of drugs on cancer stem cellsResearchers at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs)....

Droplet Array Sheds Light On Drug-Resistant Cancer Stem CellsResearchers at the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells (CSCs)....

Biodetection 2012 Conference to Address Challenges and Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012Knowledge Foundation to Bring Together Leading Organizations from around the World for the 20th Biodetection 2012 conference in Washington, DC from June 28-29, 2012 Boston, MA (PRWEB) May 09, 2012 Leading organizations from around the world will convene in Washington, DC for the Knowledge Foundation’s 20th annual Biodetection Technologies 2012 conference which will be taking place June 28th -29...

Singapore Researchers Develop Biochip To Identify Drug-Resistant CancerSingapore researchers say they have developed a biochip capable of illuminating the effect drugs have on stem cells that form the basis of cancers resistant to drugs.

Courtagen Submits Pre-IDE Information Package for the Avantra® Q400 Workstation and QPDx® BioChipCourtagen Life Sciences, Inc., a privately held life sciences company that provides innovative proteomic and genomic products and services to the life sciences industry, today announced that the company has submitted its first pre- IDE (Investigational Device Exemption) information package to the U.S. Food and Drug Administration for the Company’s Avantr...

0 1 2 3 4 ›»

buy Biochip market research data and corporate reports now Advertisement